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underestimate the complexity of both treatment and out-
comes for those with schizophrenia.
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OBJECTIVE: Medical records provide a potential wealth
of information about treatment effects; however, differ-
ences in pretreatment patient or other characteristics may
inﬂuence treatment assignment. This, in turn, could lead
to biased estimates of treatment effects in nonrandomized
studies. We developed a statistical model using propen-
sity scores to reduce treatment selection bias in analyses
based on retrospective data.
METHODS: As part of a study described elsewhere, we
abstracted retrospective data from the medical records of
327 patients treated for schizophrenia or schizoaffective
disorder with risperidone, olanzapine, or quetiapine at 
3 acute inpatient mental health facilities. Data were 
collected on patients from the inpatient hospitalization
through 60 days following initiation of study drug. Using
a multinomial logistic regression analysis of pretreatment
patient and other characteristics, we developed a predic-
tive model of treatment assignment to risperidone, 
olanzapine, or quetiapine.
RESULTS: The following variables were signiﬁcantly pre-
dictive of treatment assignment: age at admission, gender,
race, smoker at admission, history of substance abuse,
prior use of clozapine, and facility. The following vari-
ables were among those not signiﬁcantly predictive of
treatment assignment: prior use of atypical antipsychotics
other than clozapine, body mass index at admission, 
age at ﬁrst hospitalization for mental illness, and history
of suicide attempts, violence, glucose abnormalities, or
seizures.
CONCLUSION: The propensity score model offered a
means to adjust for treatment selection bias in a nonran-
domized study comparing treatment effects of risperi-
done, olanzapine, and quetiapine in an inpatient setting.
In addition, the propensity score methodology can be
used by researchers responsible for designing non-
randomized studies of healthcare interventions and 
decision-makers who are responsible for evaluating and
interpreting the results in this disease area.
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OBJECTIVES: Although effective pharmacologic treat-
ment for attention-deﬁcit/hyperactivity disorder (ADHD)
is widely available, little is know about the quality of such
care. This is unfortunate, because the burden of inappro-
priate or inadequate treatment, in terms of increased risk
for psychiatric comorbidity, chronic decrements in func-
tioning, and higher medical costs, is borne by patients,
families, employers and healthcare systems. We therefore
sought to develop a methodology to evaluate quality of
ADHD pharmacologic care.
METHODS: Among members continuously enrolled in a
pharmacy beneﬁts management plan during the year
2000, we used claims data to identify all psychostimu-
lants ﬁlled for ADHD-related treatment during a 3-month
index period (108, 819 ﬁlls for 51, 486 patients). We next
calculated average daily dose by psychostimulant class
(methylphenidate, amphetamine salts, dextroampheta-
mine, pemoline, and methamphetamine). Based upon 
previous research, we then created a metric to convert
average daily dose across psychostimulant classes into
“Methylphenidate Equivalent Units” (MEU).
RESULTS: Average daily MEU dose was 27.3mg.
Patients averaged 2.1 ﬁlls per 3-month period, at an
average of 25.5 days supplied per ﬁll. Thus, patients typ-
ically received medication coverage throughout 51 of 
the 91-day index period (56%). This is the equivalent of
receiving medication coverage for 3.9 days per week. If
medication was, in fact, taken every day, average daily
MEU dose would be nearly halved (15.3mg).
CONCLUSIONS: We describe a methodology for evalu-
ating quality of ADHD pharmacologic care. Whether
ﬁndings suggest under-treatment requires future research
linking average daily MEU dose to targeted outcomes 
of care. Guidelines recently published by the American
Academy of Pediatrics note that ADHD treatment
requires continuous monitoring “to maximize function
across multiple domains.” By incorporating our method-
ology into large-scale prescription feedback and moni-
toring systems, the burden of inappropriate or inadequate
ADHD treatment that is borne by patients, families,
employers, and healthcare systems may be ultimately 
mitigated.
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